OBJECTIVE AND METHODS: A loss-of-function cytosine (C) for thymidine (T) transition at nucleotide 8590 of CYP4A11 has been associated with increased blood pressure in humans. We tested the hypothesis that CYP4A11 T8590C genotype is associated with salt sensitivity in the International Hypertensive Pathotype cohort. RESULTS: CYP4A11 T8590C genotype was associated with hypertension in whites. Among normotensive individuals, CYP4A11 T8590C genotype was associated with mean arterial pressure (MAP) during both high and low salt diets, such that there was no relationship between genotype and salt sensitivity of blood pressure. Among hypertensive individuals, CYP4A11 T8590C genotype did not associate with MAP during high salt intake, whereas MAP decreased with increasing number of C alleles during salt restriction. Consequently, among hypertensive individuals, change in MAP with salt restriction was greatest in individuals homozygous for the C allele (-10.9 ± 9.9, -11.1 ± 12.3, and -18.8 ± 12.0 mmHg in TT, CT, and CC groups, respectively, P = 0.02). In both normotensive and hypertensive individuals, individuals homozygous for the C allele exhibited an attenuated increase in renal blood flow during high salt. CYP4A11 genotype did not affect pressor responses to Angiotensin II in normotensive or hypertensive individuals. CONCLUSION: The loss-of-function CYP4A11 8590C allele is associated with a diagnosis of hypertension and, in normotensive individuals, with higher blood pressure regardless of salt intake. Among hypertensive individuals, the C allele is associated with salt-sensitive blood pressure. Impaired renal vasodilation during high salt intake may contribute to salt sensitivity. Studies are needed to determine whether CYP4A11 T8590C genotype predicts responses to medications that affect sodium homeostasis in hypertensive individuals.
OBJECTIVE AND METHODS: A loss-of-function cytosine (C) for thymidine (T) transition at nucleotide 8590 of CYP4A11 has been associated with increased blood pressure in humans. We tested the hypothesis that CYP4A11T8590C genotype is associated with salt sensitivity in the International Hypertensive Pathotype cohort. RESULTS:CYP4A11T8590C genotype was associated with hypertension in whites. Among normotensive individuals, CYP4A11T8590C genotype was associated with mean arterial pressure (MAP) during both high and low salt diets, such that there was no relationship between genotype and salt sensitivity of blood pressure. Among hypertensive individuals, CYP4A11T8590C genotype did not associate with MAP during high salt intake, whereas MAP decreased with increasing number of C alleles during salt restriction. Consequently, among hypertensive individuals, change in MAP with salt restriction was greatest in individuals homozygous for the C allele (-10.9 ± 9.9, -11.1 ± 12.3, and -18.8 ± 12.0 mmHg in TT, CT, and CC groups, respectively, P = 0.02). In both normotensive and hypertensive individuals, individuals homozygous for the C allele exhibited an attenuated increase in renal blood flow during high salt. CYP4A11 genotype did not affect pressor responses to Angiotensin II in normotensive or hypertensive individuals. CONCLUSION: The loss-of-function CYP4A11 8590C allele is associated with a diagnosis of hypertension and, in normotensive individuals, with higher blood pressure regardless of salt intake. Among hypertensive individuals, the C allele is associated with salt-sensitive blood pressure. Impaired renal vasodilation during high salt intake may contribute to salt sensitivity. Studies are needed to determine whether CYP4A11T8590C genotype predicts responses to medications that affect sodium homeostasis in hypertensive individuals.
Authors: Bei Sun; Jonathan S Williams; Luminita Pojoga; Bindu Chamarthi; Jessica Lasky-Su; Benjamin A Raby; Paul N Hopkins; Xavier Jeunemaitre; Nancy J Brown; Claudio Ferri; Gordon H Williams Journal: J Renin Angiotensin Aldosterone Syst Date: 2011-04-13 Impact factor: 1.636
Authors: Cristiano Fava; Martina Montagnana; Peter Almgren; Lena Rosberg; Giuseppe Lippi; Bo Hedblad; Gunnar Engström; Göran Berglund; Pietro Minuz; Olle Melander Journal: Hypertension Date: 2008-06-23 Impact factor: 10.190
Authors: Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2010-02-23 Impact factor: 29.690
Authors: W Scott Watkins; Steven C Hunt; Gordon H Williams; Whitney Tolpinrud; Xavier Jeunemaitre; Jean-Marc Lalouel; Lynn B Jorde Journal: J Hypertens Date: 2010-01 Impact factor: 4.844
Authors: James V Gainer; Michael S Lipkowitz; Chang Yu; Michael R Waterman; Elliott P Dawson; Jorge H Capdevila; Nancy J Brown Journal: J Am Soc Nephrol Date: 2008-04-02 Impact factor: 10.121
Authors: Cheryl L Laffer; James V Gainer; Michael R Waterman; Jorge H Capdevila; Michal Laniado-Schwartzman; Alberto Nasjletti; Nancy J Brown; Fernando Elijovich Journal: Hypertension Date: 2008-01-28 Impact factor: 10.190
Authors: Natalie C Ward; I-Jung Tsai; Anne Barden; Frank M van Bockxmeer; Ian B Puddey; Jonathan M Hodgson; Kevin D Croft Journal: Hypertension Date: 2008-04-07 Impact factor: 10.190
Authors: Matthew E Albertolle; Donghak Kim; Leslie D Nagy; Chul-Ho Yun; Ambra Pozzi; Üzen Savas; Eric F Johnson; F Peter Guengerich Journal: J Biol Chem Date: 2017-05-22 Impact factor: 5.157
Authors: Üzen Savas; Shouzou Wei; Mei-Hui Hsu; John R Falck; F Peter Guengerich; Jorge H Capdevila; Eric F Johnson Journal: J Biol Chem Date: 2016-06-13 Impact factor: 5.157
Authors: Tina Gupta; Molly Connors; Jia Wei Tan; Worapaka Manosroi; Noha Ahmed; Pei Yee Ting; Amanda E Garza; Jose R Romero; Paul N Hopkins; Jonathan S Williams; Gordon H Williams Journal: Am J Hypertens Date: 2017-12-08 Impact factor: 2.689